JUNSHI BIO (688180.SH): Application for clinical trials of injectable JS212 has been accepted.
Junshi Biosciences (688180.SH) has issued an announcement. The company has received approval from the National Medical Products Administration for the issuance of the "Acceptance...".
JUNSHI BIO (688180.SH) announces that the company has received the "Acceptance Notification" issued by the National Medical Products Administration for the clinical trial application of injection JS212 (project code "JS212"). JS212 is a recombinant humanized dual-specific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), primarily used for the treatment of advanced malignant solid tumors.
Related Articles
Primarius Technologies (688206.SH) shareholders plan to reduce their holdings by no more than 2% in total.
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
Primarius Technologies (688206.SH) shareholders plan to reduce their holdings by no more than 2% in total.
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
RECOMMEND
